Ye Chen
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third-line therapy in patients with refractory metastatic colorectal cancer: A real-world propensity score matching study.
Journal: Journal of evidence-based medicine
Published: February 29, 2024
A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol.
Journal: Technology in cancer research & treatment
Published: February 02, 2023
Choline-induced SLC5A7 impairs colorectal cancer growth by stabilizing p53 protein.
Journal: Cancer letters
Published: June 20, 2021
Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study.
Journal: The oncologist
Published: December 27, 2020
First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component.
Journal: Cancer medicine
Published: November 20, 2020
Predictive Risk Factors and Online Nomograms for Synchronous Colon Cancer With Liver Metastasis.
Journal: Frontiers in oncology
Published: April 27, 2020
Hypomethylation of GDNF family receptor alpha 1 promotes epithelial-mesenchymal transition and predicts metastasis of colorectal cancer.
Journal: PLoS genetics
Published: April 27, 2020
Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review.
Journal: Frontiers in oncology
Published: April 10, 2020
Temporal expression and functional analysis of long non-coding RNAs in colorectal cancer initiation.
Temporal expression and functional analysis of long non-coding RNAs in colorectal cancer initiation.
Journal: Journal of cellular and molecular medicine
Published: November 08, 2018
S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.
Journal: The oncologist
Published: September 09, 2018
Selected proliferation markers correlated with dynamics of growth in colorectal cancer.
Journal: European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
Published: April 25, 2018
14-3-3zeta is involved in the anticancer effect of metformin in colorectal carcinoma.
Journal: Carcinogenesis
Published: February 02, 2018
Last Updated: 09/26/2026